{
    "relation": [
        [
            "",
            "Number of Participants Analyzed [units: participants]",
            "Area Under the Curve [units: day * microgram/mL] Geometric Mean (Geometric Coefficient of Variation)"
        ],
        [
            "Brentuximab Vedotin",
            "58",
            "98 (69%)"
        ]
    ],
    "pageTitle": "A Phase 2 Open Label Trial of Brentuximab Vedotin (SGN-35) for Systemic Anaplastic Large Cell Lymphoma - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00866047?sect=Xg015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042987866.61/warc/CC-MAIN-20150728002307-00232-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 862831687,
    "recordOffset": 862816054,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Period 1: \u00a0 Treatment Period Participant Flow for 2 periods Brentuximab vedotin 1.8 mg/kg every 3 weeks by intravenous (IV) infusion Brentuximab Vedotin Description \u00a0 Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Enrollment period: Jun 2009 - May 2010 Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: brentuximab vedotin Intervention: Lymphoma, Large-Cell, Anaplastic Lymphoma, Non-Hodgkin Conditions:",
    "textAfterTable": "NOT COMPLETED \u00a0 \u00a0 55 \u00a0 Progressive disease \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 13 \u00a0 Adverse Event \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 14 \u00a0 Physician Decision \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 14 \u00a0 Withdrawal by Subject \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 Continuing on treatment \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 9 \u00a0 [1] Number who completed 16 cycles of treatment Period 2: \u00a0 Follow-up Period \u00a0 \u00a0 Brentuximab Vedotin \u00a0 STARTED \u00a0 \u00a0 43 [1]",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}